일회용 바이오리액터 백 시장 : 세계 예측(2026-2032년)

The Single-use Bioreactor Bag Market is projected to grow by USD 2.38 billion at a CAGR of 11.29% by 2032.

Single-use Bioreactor Bags: Executive Overview

Single-use bioreactor bags are flexible, disposable vessels used to cultivate cells and microorganisms in controlled bioprocessing environments. Their adoption is associated with shorter changeover times, reduced cleaning and sterilization requirements, and lower cross-contamination risk compared with reusable stainless-steel systems. Demand is shaped by growth in biologics development, cell and gene therapy manufacturing, vaccine production, and contract bioprocessing. Key evaluation criteria include film integrity, extractables and leachables control, mixing performance, oxygen-transfer capability, scalability, sensor integration, supply continuity, and regulatory documentation.

From Fixed Infrastructure to Flexible, Modular Bioprocessing

Biomanufacturing is shifting toward modular facilities, multiproduct operations, and process platforms that can be deployed more rapidly. Single-use bags support this transition by enabling flexible production suites and reducing the facility infrastructure associated with fixed equipment. The shift also increases scrutiny of bag fit, weld quality, tubing assemblies, storage conditions, transport qualification, and disposal practices. As processes become more integrated, operators increasingly assess the bag as part of a complete system rather than as an isolated consumable.

Artificial Intelligence Strengthens Process Control and Quality Decisions

Artificial intelligence is contributing to bioprocessing through pattern recognition across sensor data, anomaly detection, predictive maintenance, and improved interpretation of process parameters. In single-use bioreactor applications, these capabilities can help identify deviations in agitation, pH, dissolved oxygen, temperature, pressure, and cell-growth behavior earlier. Effective deployment requires reliable data capture, validated analytical models, cybersecurity controls, and clear human oversight. AI does not remove the need for material qualification, sterility assurance, or documented process validation; instead, it can strengthen monitoring and decision support when integrated within regulated quality systems.

Regional Insights: Adoption Reflects Biomanufacturing Capacity and Regulation

North America benefits from established biologics manufacturing, advanced research infrastructure, and strong use of disposable processing technologies. Europe emphasizes validated supply chains, environmental considerations, and harmonized quality expectations across the European Union. Asia-Pacific combines expanding biopharmaceutical capabilities with diverse regulatory and manufacturing environments, with China, Japan, South Korea, India, and Australia each contributing distinct strengths. Latin America is developing local bioprocessing capacity while continuing to manage equipment access, technical skills, and supply-chain dependencies. The Middle East is investing in healthcare and life-science infrastructure, while Africa's opportunity is linked to strengthening pharmaceutical production, workforce capabilities, and reliable cold-chain and facility systems.

Group Insights: Trade, Regulation, and Industrial Coordination Matter

ASEAN markets are developing biomanufacturing capabilities through regional integration, improving healthcare systems, and specialized production investments. BRICS members present varied combinations of scientific capacity, domestic healthcare priorities, manufacturing policy, and regulatory maturity. The European Union supports cross-border industrial coordination and common regulatory frameworks, while the G7 includes highly developed research, healthcare, and advanced-manufacturing ecosystems. GCC countries are building life-science and healthcare capacity through infrastructure and diversification programs. NATO members span diverse biomanufacturing markets, but shared attention to resilience, critical inputs, cybersecurity, and continuity of supply is relevant to disposable bioprocessing systems.

Country Insights: Diverse Capabilities Shape Single-use Deployment

Australia combines strong research institutions with a geographically dispersed manufacturing base. Brazil and Mexico are expanding life-science capabilities while addressing import dependence, workforce development, and local production needs. Canada and the United States have mature biopharmaceutical ecosystems and substantial demand for flexible manufacturing technologies. China and India are strengthening domestic bioprocessing capacity across research, vaccines, and commercial production. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom contribute advanced research, engineering, regulatory, and manufacturing capabilities, with adoption influenced by facility modernization and sustainability priorities. Russia's bioprocessing environment is shaped by domestic production objectives, supply-chain constraints, and evolving access to specialized inputs.

Action Priorities for Leaders: Qualify, Integrate, and Build Resilience

Leaders should qualify bags against the full process window, including agitation, gas transfer, pressure, temperature, hold time, and media compatibility. Supplier assessments should examine film consistency, component traceability, quality agreements, change notification, sterility assurance, and contingency capacity. Organizations should connect bag selection with facility design, automation, sensors, and data systems rather than treating it as a procurement-only decision. They should also establish documented extractables and leachables strategies, operator training, failure-response procedures, and lifecycle plans for waste reduction and compliant disposal. AI initiatives should begin with high-quality process data, validated use cases, and governance that preserves accountable human review.

Research Methodology: Evidence-Based Market Assessment

This executive summary uses the supplied market scope-single-use bioreactor bags-and evaluates the technology through documented industry characteristics, bioprocessing applications, regional manufacturing conditions, regulatory considerations, and operational requirements. The assessment organizes insights across the required regions, country groups, and countries, emphasizing observable adoption drivers, implementation barriers, and strategic priorities. It excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Conclusions should be validated against current regulatory publications, technical documentation, facility-level operating data, and qualified supply-chain evidence before investment or procurement decisions.

Conclusion: Flexible Systems Require Disciplined Execution

Single-use bioreactor bags are an important component of modern bioprocessing because they support flexible operations, faster changeovers, and reduced cleaning complexity. Their value depends on more than disposability: material performance, system integration, quality assurance, supply resilience, operator capability, and responsible waste management determine practical outcomes. Regional and country conditions will continue to shape deployment, while AI can improve monitoring and decision support when applied within validated processes. Industry leaders that combine rigorous qualification with resilient sourcing and integrated digital operations will be better positioned to use the technology effectively.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Single-use Bioreactor Bag Market, by Bag Volume

• 7.1. Introduction
• 7.2. 50 To 200 L
• 7.3. Greater Than 200 L
• 7.4. Less Than 50 L

8. Single-use Bioreactor Bag Market, by Material

• 8.1. Introduction
• 8.2. Multi Layer Polymer
• 8.3. Polyethylene
• 8.4. Polypropylene

9. Single-use Bioreactor Bag Market, by Scale

• 9.1. Introduction
• 9.2. Bench Top
• 9.3. Commercial
• 9.4. Pilot

10. Single-use Bioreactor Bag Market, by Applications

• 10.1. Introduction
• 10.2. Cell Culture
• 10.3. Protein Production
  • 10.3.1. Monoclonal Antibodies
  • 10.3.2. Recombinant Protein
• 10.4. Vaccine Production
  • 10.4.1. Bacterial Vaccine
  • 10.4.2. Viral Vaccine

11. Single-use Bioreactor Bag Market, by End User

• 11.1. Introduction
• 11.2. Academic & Research Institutes
• 11.3. Biopharmaceutical Companies
• 11.4. Contract Manufacturing Organization

12. Single-use Bioreactor Bag Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Single-use Bioreactor Bag Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Single-use Bioreactor Bag Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ABEC, Inc.
• 16.2. Avantor, Inc.
• 16.3. Cellexus International Ltd.
• 16.4. Celltainer Biotech B.V.
• 16.5. Corning Incorporated
• 16.6. Danaher Corporation
• 16.7. Entegris, Inc.
• 16.8. Eppendorf SE
• 16.9. FUJIMORI KOGYO CO., LTD.
• 16.10. Getinge AB
• 16.11. Meissner Filtration Products, Inc.
• 16.12. Merck KGaA
• 16.13. OmniBRx Biotechnologies Pvt. Ltd.
• 16.14. Parker Hannifin Corporation
• 16.15. PBS Biotech, Inc.
• 16.16. Repligen Corporation
• 16.17. Saint-Gobain S.A.
• 16.18. Sartorius AG
• 16.19. TECNIC Bioprocess Equipment S.L.
• 16.20. Thermo Fisher Scientific Inc.

17. Key Experts